IDO1 and non-small cell lung carcinoma: The performance of the most efficient methods was subsequently evaluated in parallel in a small cohort of patients with NSCLC treated with anti-PD-1 agents, and CTC characterization according to the expression of PD-L1 and IDO was developed and optimized.